Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Carcinoma, Non-Small-Cell Lung 56Breast Neoplasms 49Ovarian Neoplasms 31Triple Negative Breast Neoplasms 27Endometrial Neoplasms 25Lung Neoplasms 24Fallopian Tube Neoplasms 22Neoplasm Metastasis 21Squamous Cell Carcinoma of Head and Neck 19Parkinson Disease 4, Autosomal Dominant Lewy Body 18Neoplasms 14Esophageal Squamous Cell Carcinoma 12Esophageal Neoplasms 12Carcinoma, Ovarian Epithelial 9Stomach Neoplasms 8Head and Neck Neoplasms 8Colorectal Neoplasms 8Carcinoma 7Adenocarcinoma Of Esophagus 7Peritoneal Neoplasms 6Adenocarcinoma 6Uterine Cervical Neoplasms 5Melanoma 5Oropharyngeal Neoplasms 4Cholangiocarcinoma 4Carcinoma, Transitional Cell 4Small Cell Lung Carcinoma 3Recurrence 3Pancreatic Neoplasms 3Mouth Neoplasms 3

Interventions

pembrolizumab 3Paclitaxel 2Carboplatin 2ulixertinib 1trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1trametinib 1selinexor 1sapanisertib 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1larotrectinib 1ipatasertib 1erdafitinib 1dostarlimab 1defactinib 1dabrafenib 1copanlisib 1capivasertib 1binimetinib 1adavosertib 1X-Rays 1Vaginal Smears 1VMBP protocol 1Trastuzumab 1Sutures 1Sunitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Uterine Neoplasms × Paclitaxel × 90 days × Clear all
NCT07044336 2026-05-20

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

AstraZeneca

Phase 3 Recruiting
700 enrolled
Gynecologic

Neoplasm Metastasis, Uterine Neoplasms, Endometrial Neoplasms

NCT06989112 2026-05-06

DE-01

AstraZeneca

Phase 3 Recruiting
600 enrolled
Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡